Pulse Biosciences, Inc. PLSE R2KR3KPHARMA
Company Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +217.09% |
| 6 Months: | +193.50% |
| 3 Months: | +110.19% |
| 1 Month: | +39.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)71.99 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PLSE Pulse Biosciences, Inc. R2KR3KPHARMA | 53.24 | -48.40 | $3.80B | 0.00% | -88.83% | -80.72% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 574.00K | 444.00K | 265.00K | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | 0 | 86.00K | 264.00K | 401.00K | 434.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 279.00K | 260.00K | 370.00K | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | -193.00K | 4.00K | 31.00K | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.04M | 20.27M | 20.17M | 18.26M | 19.18M | - |
| Operating Income | -1.23M | -1.53M | -1.68M | -2.26M | -2.77M | -2.81M | -3.20M | -6.18M | -7.49M | -8.70M | -8.67M | -9.16M | -10.76M | -8.95M | -10.08M | -11.36M | -11.75M | -13.79M | - | - | -12.90M | -18.52M | -14.81M | -14.27M | -17.27M | -14.01M | -18.02M | -9.56M | -10.23M | -11.25M | -10.62M | -11.73M | - | - | -18.04M | -20.27M | -20.37M | -18.25M | -19.15M | -25.27M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.76M | -20.00M | -20.11M | -17.99M | -18.89M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -16.80M | -19.17M | -19.39M | -17.43M | -18.58M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - | - | - | - |
| Net Income | -751.00K | -1.02M | -1.68M | -2.26M | -2.77M | -2.81M | -3.20M | -6.18M | -7.49M | -8.70M | -8.67M | -9.16M | -10.76M | -8.95M | -10.08M | -11.36M | -11.75M | -13.79M | -11.87M | -11.33M | -12.90M | -18.64M | -15.32M | -14.28M | -17.27M | -14.00M | -18.04M | -9.80M | -9.91M | -10.57M | -10.14M | -11.38M | - | - | -16.80M | -19.17M | -19.39M | -17.43M | -18.58M | -24.66M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.58 | -0.48 | - | -0.44 | -0.49 | - | - | - | - | - | - | - | -0.25 | -0.28 | -0.29 | -0.26 | -0.27 | - |
| R&D Expense | 659.00K | 951.00K | 874.00K | 1.43M | 1.55M | 1.65M | 1.73M | 2.13M | 2.92M | 2.86M | 3.17M | 3.96M | 5.04M | 5.08M | 5.84M | 6.34M | 6.19M | 6.59M | 6.18M | 5.87M | 6.97M | 9.06M | 7.46M | 6.46M | 6.77M | 5.46M | 4.52M | 5.83M | 6.70M | 7.47M | 6.74M | 7.23M | 7.70M | - | 10.31M | 12.09M | 11.39M | - | 12.59M | 16.98M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | - | 700.00K | 0 | 0 | 350.00K |
| Cost of Revenue | - | - | - | - | - | - | - | 11.94M | 0 | 0 | 539.00K |
| Gross Profit | - | - | - | - | - | - | - | -11.24M | 0 | 0 | -189.00K |
| Operating Expenses | - | - | - | - | - | - | - | 46.81M | 43.57M | 56.26M | 76.75M |
| Operating Income | -4.47M | -9.52M | -25.57M | -37.55M | -47.95M | -49.97M | - | -58.06M | -43.57M | -56.26M | -76.94M |
| EBITDA | - | - | - | - | - | - | - | -56.70M | -42.37M | -55.08M | -75.87M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | -58.51M | -42.21M | -53.59M | -72.78M |
| Tax Provision | - | - | - | - | - | - | 0 | 0 | 0 | 0 | - |
| Net Income | -2.81M | -9.52M | -25.57M | -37.55M | -46.97M | -49.85M | - | -58.51M | -42.21M | -53.59M | -72.78M |
| Diluted EPS | - | - | - | - | - | - | - | -1.69 | -0.85 | -0.92 | -1.08 |
| R&D Expense | 2.18M | 5.51M | 9.65M | 17.25M | 24.96M | 26.44M | 28.64M | 20.84M | 27.80M | 32.34M | 44.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.32M | 26.31M | 49.82M | 70.64M | 41.91M | 41.29M | - | 77.88M | 59.15M | 132.46M | 94.54M |
| Current Assets | - | - | - | - | - | - | - | - | 62.15M | 45.33M | 119.45M | 83.42M |
| Cash & Equivalents | 7.01M | 3.61M | 2.09M | 3.39M | 51.10M | 6.90M | 12.46M | - | 61.14M | 44.37M | 118.04M | 80.73M |
| Inventory | - | - | - | - | - | - | - | 5.82M | 0 | - | 0 | 136.00K |
| Receivables | - | - | - | - | - | - | - | 61.00K | 0 | - | 0 | 274.00K |
| Total Liabilities | - | - | 1.02M | 3.83M | 4.31M | 11.18M | 18.40M | - | 80.12M | 14.79M | 17.60M | 13.88M |
| Current Liabilities | - | 660.00K | 1.02M | 2.21M | 3.11M | 4.46M | 7.58M | - | 5.98M | 6.71M | 10.05M | 7.92M |
| Long Term Debt | - | - | - | - | - | - | - | - | 65.00M | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | 75.96M | 9.14M | 8.90M | 7.53M |
| Total Equity | 16.07M | 13.66M | 25.30M | 45.99M | 66.33M | 30.74M | 22.89M | - | -2.25M | 44.36M | 114.86M | 80.66M |
| Shares Outstanding | - | - | - | - | - | - | - | - | 37.87M | 56.08M | 65.93M | 67.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.32M | -8.05M | -11.09M | -23.90M | -34.19M | -35.37M | -54.10M | -47.01M | -33.04M | -36.34M | -54.12M |
| Investing Cash Flow | -86.00K | -14.38M | -23.00M | 26.12M | -10.10M | 10.04M | 7.56M | -401.00K | -121.00K | -125.00K | -335.00K |
| Financing Cash Flow | - | 20.91M | 35.38M | 45.50M | 82.00K | 30.89M | 62.69M | 79.94M | 16.39M | 110.14M | 17.15M |
| Capital Expenditure | -86.00K | -64.00K | -2.55M | -276.00K | -608.00K | -441.00K | -437.00K | -401.00K | -121.00K | -125.00K | -315.00K |
| Free Cash Flow | -3.40M | -8.12M | -13.64M | -24.17M | -34.79M | -35.81M | -54.53M | -47.41M | -33.16M | -36.47M | -54.44M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | -1,606.3% | - | - | -54.0% |
| Operating Margin % | - | - | - | - | - | - | - | -8,293.9% | - | - | -21,982.6% |
| Net Margin % | - | - | - | - | - | - | - | -8,357.9% | - | - | -20,794.6% |
| ROE % | -20.6% | -37.6% | -55.6% | -56.6% | -152.8% | -217.7% | - | 2,602.5% | -95.2% | -46.7% | -90.2% |
| ROCE % | -32.7% | -37.6% | -53.7% | -55.6% | -128.0% | -148.2% | - | -80.8% | -83.1% | -46.0% | -88.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 2.12% | 1.47M | $69.77M |
| 2 | Bank of America Corporation | 2.09% | 1.45M | $68.82M |
| 3 | Vanguard Capital Management LLC | 1.14% | 788.64K | $37.52M |
| 4 | Portolan Capital Management, LLC | 1.09% | 753.33K | $35.84M |
| 5 | Price (T.Rowe) Associates Inc | 1.08% | 748.64K | $35.61M |
| 6 | Balyasny Asset Management LP | 1.04% | 718.10K | $34.16M |
| 7 | Citadel Advisors Llc | 0.91% | 626.51K | $29.80M |
| 8 | State Street Corporation | 0.77% | 529.62K | $25.19M |
| 9 | Geode Capital Management, LLC | 0.77% | 536.28K | $25.51M |
| 10 | Massachusetts Financial Services Co. | 0.67% | 462.73K | $22.01M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PLSE
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPSDZkVDJ4STdoVmdlOUZuaHlPeFRJLXpTNGNTTnMybUNCdk04NmJhUUxOX2R4VG4wN2puWklEYnJ3bElURkdIZW9WbnZBZVJITTJUelBGWTNXZmdkZDdoS1dJNHNUMC0zZ18zdzBkZVo2RWFBcDVXb2pkRnBqVWFjSmpZYUNXbURqX0lOd2…
$PLSE stock is up 7% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNY1J6MlZTNXMwY2QwNXVFLUhJWFptbWQxN3BxSkYzNDNJY1lYcHlDQS1jRVctTS1KWFVMdTVCcm9KT0hSTG5qT0NRNkJscjRsbGY4Q2xKdWh5OTVRVkpGRjRZR2RobXp6TXcwZ1RaUERkaVRFaWF1NjFHeC1LUTltTXBDdzJJVzZraTA4QU…
COO pays nearly $50 a share for Pulse Biosciences (NASDAQ: PLSE) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOVXgxbWdEN1RUVGpKMGE5UkE3Q19wU0JOekszSS13UXpESVVuZXNmeWlRMmlzRnczQXpObjVmSzJ6NVlDVWlHaHVSY2pDSDl5U0FMdU1oVTlpcWxjcENhTjhoMzkyUFJENXdKVTFXZF9sSXplMmpGQVpwb2YybFFtQTF6TUw4LW41bTA5MH…
(PLSE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQQ3phOVNkZ0I2UWJVaDBPdzZ5TTEzZU9uQUVIckdkNDVEbW8tcjBaZmV0cE95YTAyU3NNUlJpZFZDS0E1enJid19LRWNXTHU1bDFKV1dmaFZaV0xLWDNUajJ6aHdseV9Hc2h0MXJIUVQ5cFRhSEtTU052Z2tJd0Rfb0VfVjdaTHhYZUlFUm…
Pulse Biosciences (PLSE) Grants Equity Awards to New Hires Amid High Price-to-Sales Valuation - GuruFocus
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPR3kyeXJ5dFVKWlNrYURtUVlTMmJ5LVh4NlpxMjlZb1J5Z0pjT0pDd1g1OEJQSi1RdlJHblZONEotUkFGX2hFdEt6VUlGNm5HeGFwVHBkeUoxUFQ4UTJ3cTRpXzc4bUQxZGNxemRjM3VjRWZvb1ZxekdXNlktSUZaeFJ4VnM4LVpVbVBsbT…
Pulse Biosciences COO Liane Teplitsky buys $99,971 in stock By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPblZVcFdXTTFMLXBoUVB4ZmlYVHlZN1JFejF6UTd4SzlWR18zRG1hZmVwcS01NjJtNzdqeWNpVk1BQnhjM2JjUmVTUHZhQktlanVlbUlOaFR5Q0hfUWxTYy02dmhGQy1jbmtNaDMybWM1TWtJODNxVXlkQWV3Zmdwb1QzeTAtMi1jUDRvUz…
PLSE — Frequently Asked Questions
What is the current share price of Pulse Biosciences, Inc. (PLSE)?
As of 2026-09-07 16:24 PDT, Pulse Biosciences, Inc. (PLSE) trades at $53.24 on NasdaqCM. Its 52-week range is $12.66 to $54.71.
What is the market capitalisation of PLSE?
Pulse Biosciences, Inc. (PLSE) has a market capitalisation of $3.80B on NasdaqCM.
What is the P/E ratio of PLSE?
PLSE trades at a trailing price-to-earnings (P/E) ratio of -48.40. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 43.63.
What is the return on equity (ROE) of PLSE?
PLSE has a return on equity (ROE) of -80.72%. Its return on capital employed (ROCE) is -88.83%.
Is PLSE a good stock to buy?
This page provides a data-driven analysis of Pulse Biosciences, Inc. (PLSE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.